PEN
Penumbra Inc
NYSE · Healthcare · Medical - Devices · US
$324.05
+0.51%Year over year
Reported trailing growth
- Revenue
- +17.6%
- EBITDA
- +14.8%
- EBIT
- +17.6%
- EPS
- +6.8%
- Free cash flow
- +33.6%
- Operating cash flow
- +37.9%
Forward estimates
Based on analyst estimates
- Revenue
- +16.3%
- EBITDA
- +45.5%
- EPS
- +44.6%
Three-year CAGR
- Revenue
- +18.3%
- EBITDA
- +95.5%
- EBIT
- +214.5%
- Net income
- +39.8%
- EPS
- +38.9%
- Free cash flow
- +46.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026